He ’ s an ardent believer in addressing healthcare imbalances with Digistain ’ s life-saving technology .
“ Currently , there is an inequality of care in assessing breast cancer risk for women all around the world ,” says Amrania . “ We know that recurrence is one of the greatest fears for cancer patients , but existing risk profiling tests are very expensive with results taking a long time .”
The cost of existing methods often makes testing for recurrence unaffordable and the time to receive these results significantly delays treatment decision times . Digistain wants to deliver radically faster breast
“The technology seamlessly integrates with existing pathology workflows so there is no friction to the healthcare supply chain ”
DR . HEMMEL AMRANIA FOUNDER & INVENTOR , DIGISTAIN
126 July 2023